| Literature DB >> 28526582 |
Marcela de Lima Moreira1, Moriya Tsuji2, Alexandra Jane Corbett3, Márcio Sobreira Silva Araújo1, Andréa Teixeira-Carvalho1, Olindo Assis Martins-Filho1, Vanessa Peruhype-Magalhães4, Jordana Grazziela Coelho-Dos-Reis5.
Abstract
It has been almost two decades since the discovery of mucosal-associated invariant T (MAIT)-cells. Several advances in the field have been made such as the discovery of the antimicrobial activity of MAIT-cells, the abundance of these cells in human mucosa and in liver and the discovery of ligands able to bind MR1 and activate MAIT-cells. MAIT-cells are a unique subset of innate-like T-cells that express a canonical T-cell receptor with the alpha chain containing hAV7S2 and AJ33 in humans (TCRVα7.2Jα33) and respond to bacterial/fungus vitamin B2 metabolites by an MR1-dependent pathway. Indirect activation is also observed during chronic viral infections by and IL-12/IL-18 pathway. In this review, the mechanisms of activation, the timeline of MAIT-cell development in humans as well as their role in human infection are discussed. On the whole, we believe that harnessing the anti-microbial ability of MAIT-cells could contribute for the design of potent immunotherapies and vaccines against "hard-to-kill" infectious agents that remain as public health threats worldwide.Entities:
Keywords: CD161; Infectious diseases; MAIT-cells; MR1; TCRVα7.2; TRAV1-2
Mesh:
Substances:
Year: 2017 PMID: 28526582 DOI: 10.1016/j.imlet.2017.05.007
Source DB: PubMed Journal: Immunol Lett ISSN: 0165-2478 Impact factor: 3.685